tradingkey.logo

Allurion rises after strong weight-loss data from combination therapy

ReutersNov 25, 2025 2:48 PM

Shares of healthcare firm Allurion Technologies ALUR.N rise 5.3% to $1.18 in early trading

Says patients using its swallowable gastric balloon followed by low-dose tirzepatide lost an average of 23% of their body weight over 12 months

Patients also saw lean body mass rise 14%, addressing muscle loss seen with GLP-1 drugs - ALUR

Says all 76 patients stayed on tirzepatide for full study duration, unlike typical high dropout rates

Tirzepatide, sold by Eli Lilly as Mounjaro for diabetes and Zepbound for obesity, is a GLP-1 drug that helps control blood sugar and appetite

Low-dose GLP-1 strategy aims to improve adherence and reduce side effects - ALUR

Including session's move, stock down ~90 YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI